Cardiology Associations

This page includes news coverage of cardiology societies and associations. Follow these links for specific cardiology society news pages: American College of Cardiology (ACC), American Heart Association (AHA), American Society of Echocardiography (ASE), American Society Nuclear Cardiology (ASNC), European Society of Cardiology (ESC), Heart Rhythm Society (HRS), Society for Cardiovascular Angiography Interventions (SCAI), Society of Cardiovascular Computed Tomography (SCCT), Transcatheter Cardiovascular Therapeutics (TCT), and Vascular Interventional Advances (VIVA).

A promising SELUTION: Sirolimus-eluting balloon from Cordis makes impression at TCT 2025
The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed.
Medtronic launches FDA-cleared guidewire compatible with multiple TAVR systems
The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.
'The less you drink, the better': Even minor changes in alcohol use lower hypertension risk
These new findings challenge the long-standing assumption that low levels of alcohol do not meaningfully influence a person's blood pressure.
New biodegradable PFO closure device shows early potential
Researchers tracked patients for two years, using echocardiography to confirm the devices had completely vanished. Additional studies will still be required.
Cardiology groups among the voices concerned about more medical device tariffs
When the Trump administration requested public input on adding more tariffs for PPE and all medical devices, hundreds of public comments were submitted. One common concern among those responses is that healthcare providers could be left with significantly higher costs.

ACC.24: New data suggest early PCI limits risks of vulnerable plaques—cardiologists are skeptical

The PREVENT study, presented at ACC.24, examined more than 1,600 patients with high-risk plaques treated with either preventive PCI or medical therapy alone. Outcomes were much better for the PCI group after two years, but the findings may lead to more questions than answers.

Newsweek ranked the 50 best heart hospitals in the world

ACC.24: TAVR linked to lower 1-year mortality, stroke rates than SAVR in low-risk patients

TAVR is noninferior to SAVR when treating low-risk patients, according to new data presented at ACC.24. In fact, it is associated with multiple benefits over surgery.

Foluso Fakorede, MD, interventional cardiologist, Cardiovascular Solutions of Central Mississippi, explains how he moved to rural Mississippi, the epicenter of the PAD and CLI epidemic, to open a practice to take action and reverse the glaring health disparities and that are leading to more than 400 leg amputations per day in the U.S.

Cardiologist moves to Mississippi to fight back against PAD and limit amputations

Interventional cardiologist Foluso Fakorede, MD, opened a practice in rural Mississippi, the epicenter of the PAD and CLI epidemic, to try and reverse the glaring health disparities in that region.

ACC.24 sign American College of Cardiology

ACC.24: Impella CP boosts survival for patients with STEMI-related cardiogenic shock

“This is the first time in a very long time that we have a positive study for managing cardiogenic shock,” one cardiologist said.

ACC.24: Self-expanding Evolut valves offer superior performance for TAVR patients with small annuli

The SMART trial included one-year data from TAVR patients randomized to receive either a self-expanding Evolut valve or a balloon-expandable Sapien 3 valve. All patients presented with symptomatic severe aortic stenosis and a small aortic annulus. A whopping 87% of participants were women.

semaglutide wegovy Novo Nordisk major adverse cardiovascular events

Weight loss drug semaglutide benefits obese patients presenting with HFpEF, type 2 diabetes

The new research, based on data from more than 600 patients, was presented at ACC.24 in Atlanta and published in the New England Journal of Medicine. Semaglutide is sold by Novo Nordisk under the brand name Wegovy.

ACC.24, the annual meeting of the American College of Cardiology (ACC), kicked off on Saturday, April 6, with a series of late-breaking clinical trials focused on testing the safety and effectiveness of new treatment strategies.

Day 1 at ACC.24: Late-breakers examine potential new heart attack, heart failure treatments

ACC.24 in Atlanta began Saturday, April 6, with a series of late-breaking clinical trials exploring brand new treatment strategies.

Transcatheter pulmonary valve replacement (TPVR) with Medtronic’s self-expanding Harmony valve is both safe and effective after more than a year, according to new real-world data published in the Journal of the American College of Cardiology.[1]

TPVR with self-expanding Harmony valve associated with ‘excellent’ real-world outcomes

Transcatheter pulmonary valve replacement is still linked to certain risks, researchers noted, but new data confirm it is a safe, effective treatment option for patients with severe PR.

Cardiology Associations

A promising SELUTION: Sirolimus-eluting balloon from Cordis makes impression at TCT 2025

Medtronic launches FDA-cleared guidewire compatible with multiple TAVR systems

'The less you drink, the better': Even minor changes in alcohol use lower hypertension risk

New biodegradable PFO closure device shows early potential

Cardiology groups among the voices concerned about more medical device tariffs